New Strategy for Enhancing Pharmaceutical Production in CHO Cells Revealed

Researchers from the University of California San Diego have developed a novel approach to improve pharmaceutical production in Chinese hamster ovary (CHO) cells. These cells are widely used to manufacture protein-based drugs for various diseases, including cancer and autoimmune disorders. The new strategy addresses a major limitation in CHO cells: low protein yield.

The team focused on eliminating lactic acid production, a byproduct that hinders drug production by creating a toxic environment for the cells. Instead of targeting the enzyme lactate dehydrogenase, which previous studies found essential for cell survival, the researchers identified and knocked out a network of genes controlling lactic acid production.

This innovative approach yielded promising results. The modified CHO cells stopped producing lactic acid while demonstrating improved growth and significantly higher yields of protein-based drugs like Herceptin and Rituximab. The cells also successfully produced other therapeutic proteins, including Enbrel and erythropoietin.

The study, published in Nature Metabolism, challenges long-held assumptions about cell metabolism. By eliminating the Warburg effect—a metabolic shift causing cells to overproduce lactic acid—the researchers found that CHO cells maintained normal growth rates and energy output. This suggests that the Warburg effect may not be as crucial for cell proliferation and energy production as previously thought. 

The newly engineered "Warburg-null" CHO cells are compatible with industrial cell line development processes, making them potentially easy to integrate into real-world drug production. This advancement could significantly improve the efficiency of drug manufacturing and potentially lower production costs, making life-saving therapies more affordable and accessible to patients worldwide.